Member Info for nomlungu

Looks like you robbed yourself... But, who could have expected the axe to have been so brutally swung today.

Bloodbath - another Woodford gem.

what an 'exciting' day - sell has gone through at 1.5p

Woodford Investment Management hold a third of the shares - every man and his dog knows that he may end up a forced seller. And that is most likely why the share price is falling. This may be an amazing opportunity to lose money.

tick tock - monday may be the last trading day

will there be a sell off?

https://www.politico.eu/article/uk-plans-no-deal-brexit-ad-campaign-in-europe/

how far will boris walk the plank?

Sad news - I wish him well.

If the Woodford dilema did not exist I would have considered going from watch mode to trade mode as this seems to be getting too cheap.

Freddy,

Me getting desperate? I thought that the abandoned deal with EHGO was clutching at financing straws - we have seen the significant share price decline since then.

I Spy,

You are correct - the RNS was dated 31 January. Since then they have announced a placing [21 Feb]; a convertible bond financing scheme which ended up being abandoned [26 April]; and then a further issue of equity [28 June] for abandoning the scheme.

That's 2 fund raising initiatives since the phrase was last used by Valirx.

Uncanny / Freddy,

Or they could have paid online - the online payment link is below.

https://www.epo.org/applying/online-services/fee-payment.html#tab1

Freddy,

The fees are as below but I have no idea which apply but are not significant. The point is why say in an RNS that you have been granted an EU Patent but have not paid the fees yet? I read many RNS announcements and memory says I have not read that phrase [subject to payment of the relevant fees] before. Sometimes reading between the words can give more of an insight.

https://my.epoline.org/portal/classic/epoline.Scheduleoffees

The RNS states:

'London, UK., 01 August 2019: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, announces that the European Patent Office ("EPO") has issued a Patent Notice of Allowance for ValiRx's pre-clinical therapeutic compound, VAL301, subject to payment of the relevant fees.'

Why have they not paid the 'relevant fees'? Is this a subtle reminder to shareholders that further funds will be required without which the company cannot progress the development of its compounds? As the notes to the last financial statements say:

'The company carries out regular fund-raising exercises in order that it can provide the necessary working capital for the Group. Further funds will be required to finance the Group’s work programme.'

After the calls received by some who have attended recent events I think a placing is coming sooner than most expect but at little discount / possibly a small premium to cheer the LTH who get to participate on a 2 for 10 basis. If the BOD do participate I might get tempted to speculate again.

A quick calculation - it looks as though a net of around 130 000 shares were bought today and the advertised Bid went up 10 percent. The market makers seem to have few shares and the few who post here know MAFL are trading at a discount to NAV (which will only have increased with the recent fall in the value of the £).

MAFL announced a 'Quarterly Net Asset Value and Operational Update' on the 13th of May so another can be expected in August.

I have posted before about mistakes in protein unfolding events...

https://www.wimp.com/an-astronomer-answers-twitter-questions-about-aliens/

another level?

https://www.wimp.com/an-astronomer-answers-twitter-questions-about-aliens/

Posted when there where under 800 views - now over 30k and the next debates are just starting.

The video/ad below is worth watching:

https://www.youtube.com/watch?v=CD-Y2YxQzo0

More funds are being allocated to keep the ravens alive even though the City is cutting down on maintaining the heaths.

the interweb...

https://duckduckgo.com/?q=valirx+mystic+pharmaceuticals&iar=news&ia=news

I agree - some seeking alpha articles are worth reading.